{
    "nctId": "NCT02521077",
    "briefTitle": "Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer",
    "officialTitle": "Prospective Double Blind Study of the Effect of Intravenous High Dose Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Fatigue",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Fatigue by self reported fatigue inventory questionnaire",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status score \u22642;\n* Diagnosed early stage breast cancer and scheduled to receive either adjuvant or neo-adjuvant chemotherapy;\n* Willing to receive either intravenous ascorbic acid or normal saline;\n* Willing to use an acceptable contraceptive method for the duration of the study and for 30 days following the last dose of study drug;\n* Negative urine or serum pregnancy test within 2 weeks prior to receipt of study drug;\n* Willing to complete all evaluation tools;\n* Able to give informed consent to participate in the study; and\n* Agree to avoid any additional supplemental ascorbic acid throughout the study.\n\nExclusion Criteria:\n\n* Diagnosed Glucose-6-phosphate dehydrogenase deficiency;\n* Renal insufficiency (Blood Urea Nitrogen \\>30 mg/dL, or Creatinine \\>1.5 mg/dL);\n* Unwillingness or mental incapacity to complete self-reported questionnaires;\n* Active smoker; and\n* Male sex",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}